Cargando…

RIT with Y90-Ibritumomab Tiuxetan in Follicular Non-Hodgkin Lymphoma: Evaluation of Recent Outcomes in a Single Institution

Background. Based on historical data we reviewed our hospital clinical database to analyse our updated information and therapy outcomes of follicular non-Hodgkin lymphoma (F-NHL) patients treated with (90)Y-Ibritumomab tiuxetan. Patients and Methods. Between 2005 and 2011, 56 F-NHL patients were inc...

Descripción completa

Detalles Bibliográficos
Autores principales:	Andrade Campos, Marcio Miguel, Montes Limón, Anel E., Grasa, Jose María, Lievano, Paola, Baringo, Teresa, Giraldo, Pilar
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi Publishing Corporation 2012
Materias:	Clinical Study
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3463194/ https://www.ncbi.nlm.nih.gov/pubmed/23049552 http://dx.doi.org/10.1155/2012/412742

Ejemplares similares

Update on the rational use of (90)Y-ibritumomab tiuxetan in the treatment of follicular lymphoma
por: Lehnert, Martina, et al.
Publicado: (2009)

Biodistribution, radiation dosimetry and scouting of (90)Y-ibritumomab tiuxetan therapy in patients with relapsed B-cell non-Hodgkin’s lymphoma using (89)Zr-ibritumomab tiuxetan and PET
por: Rizvi, Saiyada N. F., et al.
Publicado: (2012)

90 Y-ibritumomab tiuxetan: a nearly forgotten opportunity
por: Mondello, Patrizia, et al.
Publicado: (2015)

(90)Yttrium ibritumomab tiuxetan in the treatment of non-Hodgkin’s lymphoma: current status and future prospects
por: Jacobs, Samuel A
Publicado: (2007)

Review of (90)Y-ibritumomab tiuxetan as first-line consolidation radio-immunotherapy for B-cell follicular non-Hodgkin’s lymphoma
por: Emmanouilides, Christos
Publicado: (2009)

Efficacy of 90Y ibritumomab-tiuxetan treatment in a case of resistant gastric MALT non-Hodgkin’s lymphoma
por: Ferrucci, PF, et al.
Publicado: (2008)

(90)Y-Ibritumomab tiuxetan followed by reduced-intensity conditioning and allogeneic stem-cell transplantation in patients with advanced follicular lymphoma
por: Abou-Nassar, Karim E., et al.
Publicado: (2011)

(90)Y-ibritumomab Tiuxetan in B-cell Non-Hodgkin Lymphomas: Real-world Data From the United Arab Emirates
por: Szakács, Zsolt, et al.
Publicado: (2021)

Bulky Pulmonary Mucosa-Associated Lymphoid Tissue Lymphoma Treated with Yttrium-90 Ibritumomab Tiuxetan
por: Tamura, Shinobu, et al.
Publicado: (2013)

A new pharmacokinetic model for (90)Y-ibritumomab tiuxetan based on 3-dimensional dosimetry
por: Morschhauser, F., et al.
Publicado: (2018)

Dynamic Metabolic Changes during the First 3 Months after (90)Y-Ibritumomab Tiuxetan Radioimmunotherapy
por: Takahashi, Miwako, et al.
Publicado: (2014)

The standardized uptake value calculated from (111)In-ibritumomab tiuxetan single-photon emission computed tomography/computed tomography is a useful predictor of the clinical response in patients treated by (90)Y- ibritumomab tiuxetan therapy
por: Kume, Ayaka, et al.
Publicado: (2021)

Megadose (90)Y-ibritumomab tiuxetan prior to allogeneic transplantation is effective for aggressive large B-cell lymphoma
por: Chow, Victor A., et al.
Publicado: (2021)

90-yttrium-ibritumomab tiuxetan as first-line treatment for follicular lymphoma: updated efficacy and safety results at an extended median follow-up of 9.6 years
por: Rieger, Kathrin, et al.
Publicado: (2022)

Outcomes after (90)Yttrium-ibritumomab tiuxetan-BEAM in diffuse large B-cell lymphoma: a meta-analysis
por: Auger-Quittet, Sophie, et al.
Publicado: (2014)

Long term efficacy and safety of Fludarabine, Cyclophosphamide and Rituximab regimen followed by (90)Y-ibritumomab tiuxetan consolidation for the treatment of relapsed grades 1 and 2 follicular lymphoma
por: Pisani, Francesco, et al.
Publicado: (2015)

(90)Yttrium Ibritumomab Tiuxetan (Zevalin) for the Treatment of Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: A Report of 5 Cases
por: Wang, Jing, et al.
Publicado: (2023)

FCR (Fludarabine, Cyclophosphamide, Rituximab) regimen followed by (90)yttrium ibritumomab tiuxetan consolidation for the treatment of relapsed grades 1 and 2 follicular lymphoma: a report of 9 cases
por: Pisani, Francesco, et al.
Publicado: (2011)

Yttrium-90 ibritumomab tiuxetan plus busulfan, cyclophosphamide, and etoposide (BuCyE) versus BuCyE alone as a conditioning regimen for non-Hodgkin lymphoma
por: Jo, Jae-Cheol, et al.
Publicado: (2012)

Heterogeneity of intratumoral (111)In-ibritumomab tiuxetan and (18)F-FDG distribution in association with therapeutic response in radioimmunotherapy for B-cell non-Hodgkin’s lymphoma
por: Hanaoka, Kohei, et al.
Publicado: (2015)

90‐yttrium‐ibritumomab tiuxetan consolidation of fludarabine, mitoxantrone, rituximab in intermediate/high‐risk follicular lymphoma: updated long‐term results after a median follow‐up of 7 years
por: Casadei, Beatrice, et al.
Publicado: (2016)

Late Occurrence of PML in a Patient Treated for Lymphoma with Immunomodulatory Chemotherapies, Bendamustine, Rituximab, and Ibritumomab Tiuxetan
por: Lane, Michael A., et al.
Publicado: (2015)

The use of Yttrium-90 Ibritumomab Tiuxetan ((90)Y-IT) as a consolidation therapy in high-risk patients with diffuse large B-cell lymphoma ineligible for autologous stem-cell transplantation
por: Jurczak, Wojciech, et al.
Publicado: (2015)

Prospective SPECT-CT Organ Dosimetry-Driven Radiation-Absorbed Dose Escalation Using the In-111 ((111)In)/Yttrium 90 ((90)Y) Ibritumomab Tiuxetan (Zevalin(®)) Theranostic Pair in Patients with Lymphoma at Myeloablative Dose Levels
por: Wahl, Richard L., et al.
Publicado: (2021)

Short-course R-CHOP followed by (90)Y-Ibritumomab tiuxetan in previously untreated high-risk elderly diffuse large B-cell lymphoma patients: 7-year long-term results
por: Stefoni, V, et al.
Publicado: (2016)

Z-BeEAM (Ibritumomab tiuxetan, Bendamustine, Etoposide, Cytarabine, Melphalan) before autologous stem cell transplantation is safe and efficient for refractory large B-cell lymphoma
por: Tardy, Magalie P., et al.
Publicado: (2015)

Resistance to ibritumomab in lymphoma
por: Kumar, Lalit
Publicado: (2020)

Use of (18)F FDG PET and the short temporal response of Hodgkin's disease to RIT
por: Nowosinska, Ewa, et al.
Publicado: (2018)

Putting the Rit in cellular resistance: Rit, p38 MAPK and oxidative stress
por: Cai, Weikang, et al.
Publicado: (2013)

Bon Dieu rit : roman /
por: Saint-Amand, Edris
Publicado: (1988)

Radioimmunotherapy for mantle cell lymphoma: 5-year follow-up of 90 patients from the international RIT registry
por: Hohloch, Karin, et al.
Publicado: (2020)

Isolation, Identification, Whole-Genome Sequencing, and Annotation of Four Bacillus Species, B. anthracis RIT375, B. circulans RIT379, B. altitudinis RIT380, and B. megaterium RIT381, from Internal Stem Tissue of the Insulin Plant Costus igneus
por: Polter, Steven J., et al.
Publicado: (2015)

Aeromonas hydrophila RIT668 and Citrobacter portucalensis RIT669—Potential Zoonotic Pathogens Isolated from Spotted Turtles
por: Thomas, Seema G., et al.
Publicado: (2020)

Isolation, Whole-Genome Sequencing, and Annotation of Three Unclassified Antibiotic-Producing Bacteria, Enterobacter sp. Strain RIT 637, Pseudomonas sp. Strain RIT 778, and Deinococcus sp. Strain RIT 780
por: Schroeter, Marissa N., et al.
Publicado: (2021)

Oncogenic RIT1 mutations in lung adenocarcinoma
por: Berger, A H, et al.
Publicado: (2014)

Novel Management and Screening Approaches for Haematological Complications of Gaucher’s Disease
por: Giraldo, Pilar, et al.
Publicado: (2021)

Perspectives on metals-based radioimmunotherapy (RIT): moving forward
por: White, Jordan M., et al.
Publicado: (2021)

RIT1 regulation of CNS lipids RIT1 deficiency Alters cerebral lipid metabolism and reduces white matter tract oligodendrocytes and conduction velocities()
por: Wu, Lei, et al.
Publicado: (2023)

Recommendations on the follow‐up of patients with Gaucher disease in Spain: Results from a Delphi survey
por: Giraldo, Pilar, et al.
Publicado: (2022)

El hombre que ríe (L'homme qui rit) : novela /
por: Hugo, Victor, 1802-1885
Publicado: (1939)

Cannot write session to /tmp/vufind_sessions/sess_mtqhvrkh87mb6l0o8lfd1k7kah